Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DJH56Z
|
|||
Drug Name |
JNJ-63733657
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
Company |
Janssen
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Microtubule-associated protein tau (MAPT) | Target Info | . | [1] |
KEGG Pathway | MAPK signaling pathway | |||
Alzheimer's disease | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
EGFR1 Signaling Pathway | ||||
Pathway Interaction Database | LPA receptor mediated events | |||
Reelin signaling pathway | ||||
Reactome | Caspase-mediated cleavage of cytoskeletal proteins | |||
WikiPathways | Notch Signaling Pathway | |||
IL-2 Signaling Pathway | ||||
MAPK Signaling Pathway | ||||
Copper homeostasis | ||||
Kit receptor signaling pathway | ||||
BDNF signaling pathway | ||||
Integrated Pancreatic Cancer Pathway | ||||
Alzheimers Disease | ||||
Regulation of Microtubule Cytoskeleton | ||||
Apoptotic execution phase | ||||
IL-5 Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.